Dr. Williams received a Ph.D. in Cancer Biology from the University of Texas M.D. Anderson Cancer Center. His thesis work involved the use of prostate cancer preclinical models to conduct some of the earliest solid tumor studies of Velcade: the first proteasome inhibitor in clinical use. Dr. Williams then went on to a postdoctoral fellowship in the Department of Oncology at the Johns Hopkins School of Medicine. Under the guidance of Dr. Samuel Denmeade, Dr. Williams developed and characterized tumor-activated protoxins, and conducted studies of the role played by prostate-specific antigen (PSA) in the pathobiology of prostate cancer.
Since joining the faculty of the James Buchanan Brady Urological Institute, Dr. Williams has established research projects that seek to better understand the biology of prostate cancer, including the following:
The laboratory’s overall hypothesis is that a better understanding of prostate cancer’s biology, using clinically-relevant disease models, will lead to the discovery of new targets for therapy development.
Free Access to abstracts at PubMed
PEER REVIEWED PUBLICATIONS